Every material Form 8-K Nuvectis Pharma, Inc. has filed with the SEC since August 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Nuvectis Pharma reported third-quarter 2026 results, with a net loss of $30.1 million compared with $7.5 million a year earlier. The loss includes a one-time $20.0 million upfront payment for the NXP100 and NXP200 license agreement. The company reported $140.7 million in cash at September 30, 2026, and says this funds operations into the second half of 2029.
Net loss was $30.1 million for the quarter ended September 30, 2026, versus $7.5 million a year earlier, including a $20.0 million upfront license payment.
Basic and diluted net loss per share was $1.02, compared with $0.44 in the third quarter of 2025.
Cash and cash equivalents were $140.7 million at September 30, 2026, up from $31.6 million at December 31, 2025, after a $115.0 million follow-on offering in July.
Ciprocopan (NXP100) was approved in China in July 2026 for PNH; the company expects an update on the U.S. FDA path by year-end.
Nuvectis Pharma entered an agreement with Jefferies LLC on August 21, 2026, allowing it to sell up to $200 million of common stock through a new shelf registration. The company also ended its prior at-the-market program on July 20, 2026. Sales are not guaranteed, and shareholders could face dilution if shares are sold.
Open Market Sale Agreement with Jefferies LLC as sales agent, dated August 21, 2026
New Form S-3 shelf registration covering $200 million in securities, filed August 21, 2026
Jefferies fee of up to 3.0% of gross proceeds from ATM share sales
Prior at-the-market program terminated July 20, 2026; no further sales under it
Nuvectis reported second-quarter 2026 results with a net loss of $7.0 million, up from $6.3 million a year earlier, and cash and cash equivalents of $22.2 million at June 30, 2026. The company said a July 2026 follow-on offering raised $115 million in gross proceeds, which it says extends its cash runway into the first half of 2029. The offering adds capital for shareholders, while the reported loss grew and cash on the June 30 balance sheet was well below the $31.6 million at December 31, 2025.
Net loss was $7.0 million for the three months ended June 30, 2026, versus $6.3 million a year earlier; basic and diluted loss per share was $(0.30) in both periods.
Cash and cash equivalents were $22.2 million at June 30, 2026, compared with $31.6 million at December 31, 2025.
A July 2026 follow-on offering raised $115 million in gross proceeds, which includes the exercise of the underwriters' overallotment option.
Ciprocopan (NXP100) was approved in China in July 2026 for PNH patients not previously treated with complement inhibitors; a U.S. IND submission is expected in 4Q2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Nuvectis Pharma, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →